Oruka Therapeutics Inc (ORKA) Stock Price, Quote & News

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. T...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 606 7910

Website: orukatx.com

Address:

855 Oak Grove Avenue, Suite 100, Menlo Park, United States

MorganHoratio Jul. 2 at 10:34 PM

One of the strongest sectors outside of AI right now is Biotech. Immunology $ORKA Oruka Therapeutics $DNTH Dianthus Therapeutics $APGE Apogee Therapeutics $IMVT Immunovant $KNSA Kiniksa Pharmaceuticals Tech is rocky, and smart money is hunting for growth outside of AI. The verdict? Biotech’s Immunology & Inflammation (I&I) sector is absolutely ripping! The momentum here is insane: APGE just clocked an all-time high, DNTH launched its Phase 3 trial, smashing 52-week highs, and ORKA, IMVT, and KNSA are seeing massive inflows. I&I is starting to look like the next GLP-1 style mega-trend with its massive addressable markets and high patient stickiness. Once clinical data hits, it’s off to the moon. Can I&I outpace AI for the rest of the year? Which ticker is your top play: ORKA, DNTH, APGE, IMVT, or KNSA? Drop your picks below!

1 · Reply

Whiskeyunderthebed Jul. 2 at 7:06 PM

$ORKA Fairmount Funds increased their position yesterday on record by 6%- now owning 19.50%

0 · Reply

Samplayer_82 Jul. 2 at 4:51 PM

$ORKA is it halted?

0 · Reply

Wallstfan Jul. 2 at 2:01 PM

$ORKA anyone adding on today’s dip down $9?

2 · Reply

Whiskeyunderthebed Jul. 2 at 1:12 AM

$CADL I've been talking to myself for 6 months now on $ORKA- it's quiet there... this will be bought out for $160 -my friends...

1 · Reply

Quantumup Jul. 1 at 1:37 PM

UBS⬆️ $ORKA to $130 from $100, reiterated Buy and said, We continue to like ORKA into the H2 28-week efficacy data readout and initial durability data. $APGE - $ABBV JNJ - PTGX ALMS TAK UBS added—We believe the H2 data will likely show higher efficacy than the 16-week dataset and Skyrizi too at the same 28-week timepoint, supported by numerous psoriasis studies that generally demonstrate improving efficacy over time. While the stock has had a significant run-up, we still view it as undervalued at a ~$8-9B market cap* relative to comps including RXDX and APGE (both were acquired for $11B), particularly given its peak sales potential in a large $30 - 50B+ I&I market and potentially two differentiated assets: a long-acting IL-23 and a long-acting IL-17 A/F. We see additional 20-40%+ upside into the H2/26 data update and potentially more upside in 2027, with multiple Phase II datasets expected and the story becoming increasingly de-risked. Reiterate BUY and raise our PT to $130.

0 · Reply

Pika_Capital Jun. 30 at 5:22 PM

$ORKA this is a wild run. Taking a bit off the table again.

0 · Reply

Whiskeyunderthebed Jun. 30 at 5:13 PM

$ORKA they are really hungry today and on a tear...

0 · Reply

thesheiktrader Jun. 29 at 4:23 PM

$ORKA new palantir in pharma!!!

1 · Reply

Whiskeyunderthebed Jun. 26 at 7:51 PM

$ORKA BIG WHALES EATING the last 5 minutes into close!

0 · Reply

Oruka Therapeutics falls -8.1%

2026-07-01T11:10:49.000Z - 3 days ago

Oruka Therapeutics price target raised to $130 from $100 at UBS

Jun 3, 2026, 3:45 PM EDT - 4 weeks ago

Oruka Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 11:00 AM EDT - 4 weeks ago

Oruka Therapeutics Transcript: AGM 2026

May 28, 2026, 8:00 AM EDT - 5 weeks ago

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

2026-05-13T20:31:09.000Z - 7 weeks ago

Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)

May 13, 2026, 4:03 PM EDT - 7 weeks ago

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Oruka Therapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Oruka Therapeutics Earnings release: Q1 2026

2026-05-07T06:12:19.000Z - 2 months ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

HALO

May 6, 2026, 8:00 AM EDT - 2 months ago

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

HALO

2026-04-30T10:05:54.000Z - 2 months ago

Oruka Therapeutics price target raised to $120 from $109 at Leerink

2026-04-29T10:23:22.000Z - 2 months ago

Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright

2026-04-28T23:45:20.000Z - 2 months ago

Oruka Therapeutics $700M Secondary priced at $72.50

Apr 28, 2026, 7:42 PM EDT - 2 months ago

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

2026-04-28T12:29:34.000Z - 2 months ago

Oruka Therapeutics price target raised to $100 from $75 at UBS

2026-04-27T20:30:08.000Z - 2 months ago

Oruka Therapeutics announces $500M common stock, warrants offering

Apr 27, 2026, 4:17 PM EDT - 2 months ago

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

2026-04-27T20:15:11.000Z - 2 months ago

Oruka Therapeutics price target raised to $131 from $71 at Clear Street

2026-04-27T16:08:26.000Z - 2 months ago

Oruka Therapeutics rises 19.0%

2026-04-27T15:46:42.000Z - 2 months ago

Oruka Therapeutics price target raised to $160 from $78 at Barclays

2026-04-27T15:46:21.000Z - 2 months ago

Oruka Therapeutics price target raised to $165 from $85 at Wedbush

2026-04-27T15:30:18.000Z - 2 months ago

Oruka Therapeutics price target raised to $200 from $125 at Guggenheim

2026-04-27T14:34:43.000Z - 2 months ago

Oruka Therapeutics rises 23.5%

2026-04-27T14:25:09.000Z - 2 months ago

Oruka Therapeutics price target raised to $151 from $78 at BTIG

2026-04-27T13:27:36.000Z - 2 months ago

This Is Why Oruka Therapeutics Stock (ORKA) Soared Today

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Oruka Therapeutics Transcript: Status update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Oruka Therapeutics Press release: Status update

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Oruka Therapeutics Slides: Status update

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Apr 26, 2026, 12:00 PM EDT - 2 months ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Oruka Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Oruka Therapeutics Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Oruka Therapeutics Registration statement: Registration filing

Mar 12, 2026, 4:05 PM EDT - 4 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Oruka Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 4 months ago

Oruka Therapeutics Annual report: Q4 2025

Mar 11, 2026, 1:00 PM EDT - 4 months ago

Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Feb 9, 2026, 7:00 AM EST - 5 months ago

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Jan 15, 2026, 12:00 PM EST - 6 months ago

Oruka Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Jan 12, 2026, 7:00 AM EST - 6 months ago

Oruka Therapeutics Slides: Corporate presentation

Jan 6, 2026, 7:00 AM EST - 6 months ago

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:01 PM EST - 7 months ago

Oruka Therapeutics Announces New Board Member and Board Transition

Nov 12, 2025, 4:05 PM EST - 8 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:00 PM EST - 8 months ago

Oruka Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 8 months ago

Oruka Therapeutics Quarterly report: Q3 2025

Nov 11, 2025, 4:40 PM EST - 8 months ago

Oruka Therapeutics Transcript: Stifel 2025 Healthcare Conference

Oct 29, 2025, 7:00 AM EDT - 8 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 9 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 9 months ago

Oruka Therapeutics Registration statement: Registration Filing

Sep 18, 2025, 7:15 AM EDT - 10 months ago

Oruka Therapeutics Slides: Study Presentation

Sep 18, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics Slides: Corporate Presentation

Sep 18, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics Slides: Study Presentation

Sep 17, 2025, 1:02 AM EDT - 10 months ago

Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:00 AM EDT - 10 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Aug 11, 2025, 4:04 PM EDT - 11 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Oruka Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Oruka Therapeutics Quarterly report: Q2 2025

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 1, 2025, 4:01 PM EDT - 1 year ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

May 21, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 14, 2025, 4:15 PM EDT - 1 year ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 12:00 AM EDT - 1 year ago

Oruka Therapeutics Quarterly report: Q1 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 6, 2025, 4:09 PM EST - 1 year ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Annual report: Q4 2024

Mar 4, 2025, 10:30 AM EST - 1 year ago

Oruka Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Dec 19, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Nov 14, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Registration statement: Registration Filing

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Earnings release: Q3 2024

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Sep 25, 2024, 7:08 AM EDT - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 12, 2024, 7:05 AM EDT - 1 year ago

Oruka Therapeutics Announces $200 Million Private Placement

Aug 29, 2024, 4:50 PM EDT - 2 years ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 26, 2024, 7:30 PM EDT - 2 years ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 2 years ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 1, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 6:34 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 25, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 5, 2024, 1:27 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 3, 2024, 11:38 AM EDT - 2 years ago

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 7:30 AM EDT - 2 years ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Feb 1, 2024, 4:35 PM EST - 2 years ago

ARCA biopharma Announces 2023 Financial Results

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 18, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

Feb 24, 2023, 4:20 PM EST - 3 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Dec 19, 2022, 4:05 PM EST - 3 years ago

James Flynn Joins ARCA biopharma Board of Directors

MorganHoratio Jul. 2 at 10:34 PM

1 · Reply

Whiskeyunderthebed Jul. 2 at 7:06 PM

$ORKA Fairmount Funds increased their position yesterday on record by 6%- now owning 19.50%

0 · Reply

Samplayer_82 Jul. 2 at 4:51 PM

$ORKA is it halted?

0 · Reply

Wallstfan Jul. 2 at 2:01 PM

$ORKA anyone adding on today’s dip down $9?

2 · Reply

Whiskeyunderthebed Jul. 2 at 1:12 AM

$CADL I've been talking to myself for 6 months now on $ORKA- it's quiet there... this will be bought out for $160 -my friends...

1 · Reply

Quantumup Jul. 1 at 1:37 PM

0 · Reply

Pika_Capital Jun. 30 at 5:22 PM

$ORKA this is a wild run. Taking a bit off the table again.

0 · Reply

Whiskeyunderthebed Jun. 30 at 5:13 PM

$ORKA they are really hungry today and on a tear...

0 · Reply

thesheiktrader Jun. 29 at 4:23 PM

$ORKA new palantir in pharma!!!

1 · Reply

Whiskeyunderthebed Jun. 26 at 7:51 PM

$ORKA BIG WHALES EATING the last 5 minutes into close!

0 · Reply

Whiskeyunderthebed Jun. 25 at 2:47 PM

$ORKA It sure looks like this is trying to adjust to a BO number.

0 · Reply

Nasdaq_Frontier Jun. 24 at 8:53 PM

There is always a bull market somewhere. Industrials Financials Healthcare Real Estate Most traders ignore sector rotation until it's obvious. By then the easy money is gone. Here are the names I'm watching in each sector: Healthcare: $OSCR $ORKA $UNH $ILMN $NVTS I have exposure in Industrials. Finance and plenty of Healthcare stocks. Bookmark this. The leaders are quietly rotating while everyone's still watching the same 7 tech names.

0 · Reply

Quantumup Jun. 23 at 12:12 PM

H.C. Wainwright reiterated $ORKA Buy-$120 UCBJY JNJ - PTGX ALMS TAK H.C. Wainwright commented on y'day's $APGE and $ABBV M&A deal, pointing to Apogee's similarity to Oruka, as it was incepted by privately-held Paragon Therapeutics, and additionally said: In our view, Oruka and Apogee have many points of commonality, including a focus on I&I (particularly inflammatory skin diseases) and the intent to advance investigational agents with best-in-disease potential. We reiterate our Buy rating and 12-month price target of $120 per share.

0 · Reply

Stocks_and_Stacks Jun. 23 at 6:06 AM

🚀 Bulls stacking wins on Monday June 22 with biotech catalysts, small-cap volume surges, and AI infrastructure momentum! 🐂📈 First off 😎 who’s all up late studying charts and getting ready for tomorrow? Our group just received two new banger alerts that have serious 100-200% run potential. Eyes sharp, bulls! Huge congrats to everyone riding these top 5 movers today. $APGE +46.7% – Apogee Therapeutics surging on positive biotech pipeline news and strong institutional buying. $DFTX +49.8% – Definium Therapeutics exploding on clinical catalyst and speculative small-cap momentum. $SMCI + momentum – Super Micro Computer lifting on new AI data center blueprint with Nvidia tech. $ORKA +18% – Oruka Therapeutics climbing on healthcare sector rotation and volume surge. $HQ +20% – Horizon Quantum Holdings gaining on quantum/AI interest and breakout action. Solid start to the week with resilience, bulls 😎 #TopMovers #BullMarket #Stocks #BangerAlerts #BiotechRally

1 · Reply

Spicy_Trade Jun. 22 at 11:50 PM

Oruka Therapeutics, Inc. ( $ORKA ) SpicyTrade - Daily Stock Analysis https://youtu.be/O8yERqppk-g?si=6TZPVJ8HW6GiEsnG

0 · Reply

Whiskeyunderthebed Jun. 22 at 5:50 PM

$ORKA double the volume already-BIG WHALE bought today!

0 · Reply

Whiskeyunderthebed Jun. 22 at 5:01 PM

$ORKA Being sold for $160

0 · Reply

thesheiktrader Jun. 22 at 4:59 PM

$ORKA never miss with orka…. Waiting the +100 is coming..

0 · Reply

Pika_Capital Jun. 22 at 2:16 PM

$APGE $SYRE $ORKA absolutely WILD day for pfolio

4 · Reply

NeverFadeTheOracle Jun. 22 at 12:06 PM

$APGE $ABBV rumored to buy Was just about to post here today Fits my bio space, DERM, Respiratory, And now Gastro. 😭 $SYRE $ORKA

0 · Reply

Pika_Capital Jun. 21 at 4:25 PM

All 3 $ORKA $APGE $SYRE massive winners for Pika. If APGE is taken out tomorrow I expect other 2 to follow eventually.

1 · Reply

Market Cap	5.14B
Revenue (ttm)	0.00
Net Income (ttm)	-105.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,524,000
Avg Vol	1,946,550
Day's Range	N/A - N/A
Shares Out	60.31M
Stochastic %K	33%
Beta	-0.35
Analysts	Strong Sell
Price Target	$143.62